Effect of R&D expenditures and funding strategies on the market value of biotech firms

Journal of Engineering and Technology Management - JET-M

Volumn 12, Issue 4, 1996, Pages 287-299

  McCutchen Jr , William W ^a   Swamidass, Paul M ^b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Biotech firm market value; Biotech R D costs; Biotech research funding

Indexed keywords

BIOTECHNOLOGY; COSTS; INDUSTRIAL ECONOMICS; INDUSTRIAL MANAGEMENT; INDUSTRIAL RESEARCH; MATHEMATICAL MODELS; REGRESSION ANALYSIS; STRATEGIC PLANNING;

BIOTECHNOLOGY FIRMS;

RESEARCH AND DEVELOPMENT MANAGEMENT;

EID: 0029712123     PISSN: 09234748     EISSN: None     Source Type: Journal    
DOI: 10.1016/0923-4748(95)00014-3     Document Type: Article

References (24)

1. Arora, A. and Gambardella A., 1990. Complementarity and external linkages: The strategies of the large firms in biotechnology. The Journal of Industrial Economics, 38(4), June: 361-379.
2. Berenson, M.L. and Levine D.H., 1986. Basic Business Statistics, 3rd ed. Prentice-Hall, Englewood, NJ.
3. Brealey, R.A. and Myers S.C., 1988. Principles of Corporate Finance. McGraw-Hill Co, New York.
4. Burrill, G.S., 1990. Biotech 90: Into the Next Decade. Mary Ann Liebert, New York.
5. Bylinsky, G., 1991. Biotech firms tackle the giants. Fortune, Aug. 12: 78-82.
6. Caglarcan, E., 1977. Economics of innovation in the pharmaceutical industry. Unpublished Ph.D. dissertation. George Washington University.
7. Cool, K. and Schendel D., 1987. Strategic group formation and performance: The case of the U.S. pharmaceutical industry, 1963-1982. Management Science, 33(9): 1102-1124.
8. Cool, K. and Schendel D., 1988. Performance differences among strategic group members. Strategic Management Journal, 9: 207-223.
9. Dibner, M.D., 1988. Biotechnology Guide - USA. Stockton Press, New York, NY.
10. Eli Lilly and Company, 1990. Third Quarter Report, p. 12.
11. Fildes, R.A., 1990. Strategic challenges in commercializing biotechnology. California Management Review, 32(3): 63-72.
12. Franko, L.G., 1989. Global corporate competition: who's winning, who's losing, and the R&D factor as one reason why. Strategic Management Journal, 10: 449-474.
13. Gartrell, K.D., 1990. Innovation, industry specialization and stockholder wealth. California Management Review, Spring: 87-101.
14. Grabowski, H.G. and Vernon, J., 1981. The determinants or research and development expenditures in the pharmaceutical industry. In: R. Helms (Ed.), Drugs and Health. American Enterprise Institute, Washington, DC, pp. 3-21.
15. Hamilton, W.F., Vila J. and Dibner, M., 1990. Patterns of strategic choice in emerging firms: Positioning for innovation in biotechnology. California Management Review, Spring: 73-86.
16. McCutchen, W.W., 1993a. Strategy changes as response to alteration in tax policy. Journal of Management.
17. McCutchen, W.W., 1993b. Estimating the impact of the R&D tax credit on strategic groups in the pharmaceutical industry. Research Policy, 22: 337-351.
18. Patterson, T.D., 1988. The business of biotech. World, Winter: 40-45.
19. Pisano, G.P., 1990. The R&D boundaries of the firm: An empirical analysis. Administrative Science Quarterly, 35: 153-176.
20. Quinn, J.B., 1992. The intelligent enterprise: A new paradigm. Academy of Management Executive, Vol VI, No. 4, November: 48-63.
21. Smith, J.G. and Fleck V., 1988. Strategies of new biotechnology firms. Long Range Planning, 21(3): 51-58.
22. Snee, R.D., 1973. Some aspects of nonorthogonal data analysis, Part I: Developing prediction equations. Journal of Quality Technology, 5: 67-79.
23. Sudharshan, D., Thomas H. and Fiegenbaum A., 1985. Strategic time periods and strategic groups research: Concepts and an empirical example. Research paper, University of Illinois at Urbana-Champaign.
24. Sudharshan, D., Thomas H. and Fiegenbaum A., 1986. Mobius - a procedure for identifying mobility barriers based on dynamic strategic grouping analysis. Working Paper No. 1226, University of Illinois at Urbana-Champaign.